Data protection Impressum

Newsroom

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (July 2026)

3 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

Hilo closes a USD 19 million Series B extension to fuel its US expansion

3 August 2026

Actival, a CSEM spin-off based in Neuchâtel, has been awarded a CHF 1.4 million grant from Innosuisse to accelerate the development and market launch of its patented Active Splints, a new generation of dental aligners that dispense antibacterial fluid and fluoride.

Actival secures a CHF 1.4 million Innosuisse grant for its smart dental aligners

3 August 2026

MoleSense and Impli, both based at the Biopôle life sciences campus, have been selected by Germany's Federal Agency for Breakthrough Innovation to develop biosensors capable of continuously measuring at least four hormones over seven days.

MoleSense and Impli selected for the SPRIND Challenge on continuous hormone monitoring

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

HeroSupport, a Geneva-based medtech company, has announced that NYU Grossman School of Medicine is the first clinical site in the United States to participate in its SHIELD study evaluating the VENUS SHELL breast immobilization device.

HeroSupport opens its first US clinical site for the SHIELD study

3 August 2026

Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.

Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong

3 August 2026

SWISSto12, the Renens-based space technology company and EPFL spin-off, has closed a USD 70 million Series C round to meet growing demand for its payloads and satellites across multiple orbits.

SWISSto12 raises USD 70 million to meet growing multi-orbit satellite demand

16 July 2026

Switzerland has once again topped the European Innovation Scoreboard, ranking first among all EU Member States and neighboring countries in the 2026 edition, its ninth consecutive year at the top, with a performance of 141.3% of the EU average.

Switzerland leads the European Innovation Scoreboard 2026 for the ninth consecutive year

14 July 2026

1 2 3 4 5 … 94